38 research outputs found
Device Thrombogenicity Emulation: A Novel Method for Optimizing Mechanical Circulatory Support Device Thromboresistance
Mechanical circulatory support (MCS) devices provide both short and long term hemodynamic support for advanced heart failure patients. Unfortunately these devices remain plagued by thromboembolic complications associated with chronic platelet activation – mandating complex, lifelong anticoagulation therapy. To address the unmet need for enhancing the thromboresistance of these devices to extend their long term use, we developed a universal predictive methodology entitled Device Thrombogenicity Emulation (DTE) that facilitates optimizing the thrombogenic performance of any MCS device – ideally to a level that may obviate the need for mandatory anticoagulation
Attenuation of myogenic orofacial nociception and mechanical hypersensitivity by viral mediated enkephalin overproduction in male and female rats
Assimilation of preexisting Pleistocene intrusions at Long Valley by periodic magma recharge accelerates rhyolite generation: rethinking the remelting model
Transcatheter Pulmonary Valve Replacement by Hybrid Approach Using a Novel Polymeric Prosthetic Heart Valve: Proof of Concept in Sheep
ReliantHeart: Forward Compatibility and TET
ReliantHeart (ReliantHeart Inc., Houston, TX, USA)
HeartAssist5 (HA5) left ventricular assist device
(LVAD) system is a miniaturized, implantable, second-
generation axial-flow pump capable of longterm
circulatory support in patients with end-stage
heart failure. The device results to be the first continuous-
flow LVAD ever implanted in human being.
This compact axial-flow pump has been in development
since 1988 named as MicroMed DeBakey
[1] (MicroMed Cardiovascular Inc., Houston, TX,
USA) whose design belongs to the second-generation
pump category [2, 3]